RecruitingPHASE2, PHASE3NCT05416307
Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
Studying Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Electra Therapeutics Inc.
- Principal Investigator
- Medical DirectorElectra Therapeutics Inc.
- Intervention
- ELA026(drug)
- Enrollment
- 156 enrolled
- Eligibility
- 6 years · All sexes
- Timeline
- 2022 – 2029
Study locations (30)
- University of Alabama at Birmingham School of Medicine, Birmingham, Alabama, United States
- Phoenix Children's Hospital, Phoenix, Arizona, United States
- University of California, Los Angeles, Los Angeles, California, United States
- MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Children's Healthcare of Atlanta - Center for Advanced Pediatrics, Atlanta, Georgia, United States
- Emory University, Atlanta, Georgia, United States
- Columbia University, New York, New York, United States
- Cornell University, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
- Texas Children's Hospital, Houston, Texas, United States
- University of Texas MD Anderson Cancer Center, Houston, Texas, United States
- Huntsman Cancer Institute, Salt Lake City, Utah, United States
- Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location, Seattle, Washington, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05416307 on ClinicalTrials.govOther trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07525466Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)Beijing Tongren Hospital
- RECRUITINGPHASE4NCT07270835Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell LymphomaThe First Affiliated Hospital of Soochow University
- RECRUITINGNANCT07488728Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisBeijing Children's Hospital
- RECRUITINGPHASE2NCT06160791Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)Jerry Lee, MD, MSc, MPhil
- ACTIVE NOT RECRUITINGNCT06587191Emapalumab Efficacy in Children With Primary Hemophagocytic LymphohistiocytosisFederal Research Institute of Pediatric Hematology, Oncology and Immunology
- RECRUITINGNCT06339177Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE StudyNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT06614998Establishment of an Early Warning Screening System for Hemophagocytic Lymphohistiocytosis a Multi-center, Prospective StudyThe Affiliated Hospital of Xuzhou Medical University
- RECRUITINGNCT06585124Flow Cytometry for the Study of T-Cell Populations in Hemophagocytic Lymphohistiocytosis Associated With LymphomasFondazione Policlinico Universitario Agostino Gemelli IRCCS
See all trials for Acquired hemophagocytic lymphohistiocytosis associated with malignant disease →